Soligenix Appoints Former White House Economic Advisor Tomas J. Philipson to Strategic Role

Soligenix Inc. has appointed Tomas J. Philipson, PhD as a Strategic Advisor to provide guidance on the company's rare disease treatment pipeline. Philipson brings extensive experience in U.S. economic and healthcare policy, having previously served as acting chairman of the White House Council of Economic Advisers and advised major healthcare regulatory bodies including the FDA and CMS. His background includes academic, business, and government roles that position him to assist Soligenix in navigating complex regulatory pathways.

The appointment comes at a critical time for Soligenix as the company advances its lead product candidate HyBryte through confirmatory Phase 3 trials for cutaneous T-cell lymphoma. Christopher J. Schaber, PhD, CEO of Soligenix, emphasized that Philipson's expertise and relationships will be instrumental in the commercialization process. The company's pipeline includes multiple rare disease treatments, with HyBryte representing a novel photodynamic therapy using safe visible light technology.

Philipson currently serves as Managing Partner of MEDA Ventures and holds positions on several corporate boards, bringing additional business acumen to Soligenix's strategic planning. His appointment signals the company's commitment to strengthening its regulatory and commercialization capabilities as it prepares for potential market entry. Additional information about the company's developments is available at https://ibn.fm/SNGX.

Soligenix's broader pipeline includes expansion of synthetic hypericin into psoriasis treatment, innate defense regulator technology for inflammatory diseases, and vaccine programs targeting ricin toxin, filoviruses, and COVID-19. The Public Health Solutions business segment has received government funding from agencies including NIAID, DTRA, and BARDA. Philipson's experience with government health initiatives aligns with these ongoing partnerships.

The strategic advisory role will focus on optimizing the development pathway for Soligenix's rare disease portfolio, particularly as the company approaches potential regulatory submissions. Philipson expressed commitment to supporting the company's mission of addressing unmet medical needs in rare diseases. His background in healthcare economics provides valuable perspective on market access and reimbursement strategies that will be crucial for successful commercialization.